Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:CMND 13 November 2025 - 18 November 2025

Clearmind Medicine (CMND) Delivers Positive AUD Trial Data Amid New Depression Patent – Nov. 18, 2025

Clearmind Medicine (CMND) Delivers Positive AUD Trial Data Amid New Depression Patent – Nov. 18, 2025

Clearmind Medicine reported positive safety results from the first cohort of its FDA-approved Phase I/IIa trial of CMND-100 for alcohol use disorder. No serious adverse events were observed among six participants treated at Johns Hopkins and Yale. CMND shares surged to $0.39 intraday on heavy volume before settling near $0.27 by mid-afternoon November 18. The company also announced a new Israeli patent filing and an expected equity offering.
18 November 2025
··
Clearmind Medicine (CMND) Stock Soars as FDA‑Regulated Alcohol Use Disorder Trial Expands to Hadassah – November 13, 2025

Clearmind Medicine (CMND) Stock Soars as FDA‑Regulated Alcohol Use Disorder Trial Expands to Hadassah – November 13, 2025

Clearmind Medicine shares surged Thursday after the company received final approval to expand its FDA-regulated Phase 1/2a trial for Alcohol Use Disorder to Hadassah Medical Center in Jerusalem. The firm also filed for a registered direct offering of shares and pre-funded warrants, raising new capital but prompting dilution concerns among investors. The trial now includes sites at Yale, Johns Hopkins, Tel Aviv Sourasky, and Hadassah.
13 November 2025
··

Stock Market Today

  • Is General Electric Stock Fairly Valued After Recent Pullback?
    March 20, 2026, 11:49 AM EDT. General Electric's (GE) shares have dropped 4.9% in the past week and 10.8% over 30 days, yet the stock remains close to its intrinsic value. A Discounted Cash Flow (DCF) model estimates GE's fair value at about $272.33 per share, slightly below the current $291.61 price, suggesting the shares are roughly 7.1% overvalued. Despite a 43.8% return over the last year, GE's performance is now lagging behind peers amid shifts in capital goods, regulation, and company factors. Investors should monitor free cash flow estimates and valuation metrics like the price-to-earnings ratio to gauge potential risks and opportunities.
Go toTop